Document › Details
Cetero Research. (11/16/10). "Press Release: Cetero Research Expands Business Development in Europe. Respected Industry Leader to Enhance Cetero’s Success in the EU". Cary, NC.
|Organisation||Cetero Research (Group)|
|Organisation 2||Icon plc|
|Group||Icon plc (Group)|
|Person||Pullen, Marcus (Cetero Research 201011– Senior Director BusDev Europe before Icon Development Solutions BusDev)|
|Person 2||Capicchioni, John (Cetero Research 201011 President Business Development)|
Cetero Research, the leading early-stage contract research organization (CRO), today announced the appointment of Marcus Pullen as Senior Director, Business Development, based in the United Kingdom. Pullen will be Cetero's first business development representative in Europe for new business opportunities.
With more than 15 years of experience working for international CROs, Pullen has extensive knowledge of early-stage clinical trials. He has spent his career based in the United Kingdom, building relationships across Europe and Asia.
"We are excited to have Marcus as part of the Cetero team," said John Capicchioni, Vice President, Business Development, of Cetero Research. "We are seeing extraordinary business opportunities and growth across Europe given the comprehensive scope of early-stage services that Cetero provides. With Marcus in Europe, more clients will gain an understanding of the services that Cetero offers in clinical pharmacology, bioanalytical, scientific affairs and development consultancy services."
Prior to joining Cetero, Pullen served as Senior Director of Business Development at ICON Development Solutions. As a senior industry professional with a track record of high performance, Pullen's main responsibilities were to advance business opportunities with new clients in the biotech and pharmaceutical industries and manage key accounts within the company's existing client base.
"European pharmaceutical, biotech and generic companies value CROs that implement industry-leading best practices," said Troy W. McCall, Ph.D., CEO of Cetero Research. "Cetero emphasizes strong science and innovative study designs that are supported by world-class quality and service. We are very fortunate to have him as our first European business development representative."
About Cetero Research
Cetero Research is the leading early-stage contract research organization (CRO). With more than 25 years of experience from its founding companies, Cetero has conducted more than 10,000 clinical pharmacology studies - more than any other CRO. Cetero's proven track record allows the company to provide flexible and high-quality drug-development services. The company's time-tested systems produce consistent and reliable data clients can trust. Cetero's clinical research expertise consists of traditional early-stage, healthy-volunteer clinical pharmacology and bioavailability studies, as well as specialty Phase Ia/b trials in patients. Its bioanalytical services support clinical, preclinical drug and biomarker analysis for small and large molecules. For more information, visit www.cetero.com, or call 877.7CETERO.
# # #
For more information, please contact:
Vice President, Business Relationship Management
Direct Line: 919-468-4214
Record changed: 2016-03-19
More documents for Cetero Research (Group)
-  Cetero Research. (7/27/11). "Press Release: Cetero Research Responds to FDA Untitled Letter". Cary, NC....
-  FDA. (7/26/11). "Press Release: FDA Notifies Pharmaceutical Companies that Studies Conducted by Cetero Research May Require Reevaluation"....
-  Cetero Research. (9/2/10). "Corporate Information by E-Mail"....
-  Cetero Research. (8/19/10). "Press Release: Cetero Research Announces Expansion of TDDS and Dermatology Services to Four Clinical Facilities". Cary, NC....
-  Cetero Research. (10/17/06). "Press Release: Labs Merge, Become World’s Largest in Early Clinical & Bio-analytical Research"....
To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to email@example.com and simply fill the subject line with the word »MSC newsletter«
To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]